Switch theme
Sign up to access all valuation multiples
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
2015
36
LTM Revenue $21.6M
LTM EBITDA -$26.3M
$215M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mereo BioPharma Group has a last 12-month revenue (LTM) of $21.6M and a last 12-month EBITDA of -$26.3M.
In the most recent fiscal year, Mereo BioPharma Group achieved revenue of n/a and an EBITDA of -$40.8M.
Mereo BioPharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mereo BioPharma Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $21.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$26.3M | XXX | -$40.8M | XXX | XXX | XXX |
| EBITDA Margin | -122% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$29.6M | XXX | -$45.7M | XXX | XXX | XXX |
| EBIT Margin | -137% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$29.2M | XXX | -$43.3M | XXX | XXX | XXX |
| Net Margin | -135% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Mereo BioPharma Group's stock price is $2.
Mereo BioPharma Group has current market cap of $277M, and EV of $215M.
See Mereo BioPharma Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $215M | $277M | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Mereo BioPharma Group has market cap of $277M and EV of $215M.
Mereo BioPharma Group's trades at 21.5x EV/Revenue multiple, and -5.3x EV/EBITDA.
Equity research analysts estimate Mereo BioPharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mereo BioPharma Group has a P/E ratio of -9.5x.
See valuation multiples for Mereo BioPharma Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $277M | XXX | $277M | XXX | XXX | XXX |
| EV (current) | $215M | XXX | $215M | XXX | XXX | XXX |
| EV/Revenue | 10.0x | XXX | 21.5x | XXX | XXX | XXX |
| EV/EBITDA | -8.2x | XXX | -5.3x | XXX | XXX | XXX |
| EV/EBIT | -7.3x | XXX | -4.7x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.5x | XXX | -6.4x | XXX | XXX | XXX |
| EV/FCF | -11.6x | XXX | -6.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMereo BioPharma Group's last 12 month revenue growth is 81%
Mereo BioPharma Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Mereo BioPharma Group's rule of 40 is -180% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mereo BioPharma Group's rule of X is 81% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mereo BioPharma Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 81% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -122% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -90% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -180% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 81% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mereo BioPharma Group acquired XXX companies to date.
Last acquisition by Mereo BioPharma Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Mereo BioPharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mereo BioPharma Group founded? | Mereo BioPharma Group was founded in 2015. |
| Where is Mereo BioPharma Group headquartered? | Mereo BioPharma Group is headquartered in United States of America. |
| How many employees does Mereo BioPharma Group have? | As of today, Mereo BioPharma Group has 36 employees. |
| Who is the CEO of Mereo BioPharma Group? | Mereo BioPharma Group's CEO is Dr. Denise Vera Scots-Knight, PhD. |
| Is Mereo BioPharma Group publicy listed? | Yes, Mereo BioPharma Group is a public company listed on NAS. |
| What is the stock symbol of Mereo BioPharma Group? | Mereo BioPharma Group trades under MREO ticker. |
| When did Mereo BioPharma Group go public? | Mereo BioPharma Group went public in 2018. |
| Who are competitors of Mereo BioPharma Group? | Similar companies to Mereo BioPharma Group include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Mereo BioPharma Group? | Mereo BioPharma Group's current market cap is $277M |
| What is the current revenue of Mereo BioPharma Group? | Mereo BioPharma Group's last 12 months revenue is $21.6M. |
| What is the current revenue growth of Mereo BioPharma Group? | Mereo BioPharma Group revenue growth (NTM/LTM) is 81%. |
| What is the current EV/Revenue multiple of Mereo BioPharma Group? | Current revenue multiple of Mereo BioPharma Group is 10.0x. |
| Is Mereo BioPharma Group profitable? | Yes, Mereo BioPharma Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mereo BioPharma Group? | Mereo BioPharma Group's last 12 months EBITDA is -$26.3M. |
| What is Mereo BioPharma Group's EBITDA margin? | Mereo BioPharma Group's last 12 months EBITDA margin is -122%. |
| What is the current EV/EBITDA multiple of Mereo BioPharma Group? | Current EBITDA multiple of Mereo BioPharma Group is -8.2x. |
| What is the current FCF of Mereo BioPharma Group? | Mereo BioPharma Group's last 12 months FCF is -$18.5M. |
| What is Mereo BioPharma Group's FCF margin? | Mereo BioPharma Group's last 12 months FCF margin is -86%. |
| What is the current EV/FCF multiple of Mereo BioPharma Group? | Current FCF multiple of Mereo BioPharma Group is -11.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
